home / stock / bysi / bysi news

BYSI News and Press, BeyondSpring Inc. From 02/26/19

Stock Information
Company Name: BeyondSpring Inc.
Stock Symbol: BYSI
Market: NASDAQ
Website: beyondspringpharma.com
Menu
BYSI BYSI Quote BYSI Short BYSI News BYSI Articles BYSI Message Board
Get BYSI Alerts

News, Short Squeeze, Breakout and More Instantly...
BYSI - BeyondSpring's Plinabulin shows positive action in mid-stage breast cancer study

New data from a Phase 2 clinical trial, Study 106 , evaluating BeyondSpring's ( BYSI +0.1% ) lead drug Plinabulin compared to Amgen's ( AMGN +0.1% ) Neulasta (pegfilgrastim) in reducing the duration of severe neutropenia (abnormally low levels of a type of white blood cell) in certai...
BYSI - New Data Shows Addition of BeyondSpring's Plinabulin Reverses Neulasta's Potential Immune-Suppressive Phenotype in Treating Chemotherapy-Induced Neutropenia

BeyondSpring to Present Results at 2019 ASCO-SITC Clinical Immuno-Oncology Symposium   NEW YORK, Feb. 26, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced new ...

BYSI - BeyondSpring Announces Positive Pre-NDA Meeting with the U.S. FDA for its Lead Asset, Plinabulin

NEW YORK, Dec. 27, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it had a positive pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administrat...

BYSI - United States Patent and Trademark Office Issues Composition of Matter Patent with BeyondSpring's Lead Asset Plinabulin with Protection to 2036

NEW YORK, Dec. 21, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the United States Patent and Trademark Office (USPTO) has issued the Company U.S. Patent No. 1...
BYSI - BeyondSpring Strengthens Intellectual Property Portfolio with Newly Granted U.S. Patent for Plinabulin

NEW YORK, Sept. 19, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the U.S. Patent and Trademark Office (USPTO) has granted the Company a new pat...

Previous 10 Next 10